Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Pharvaris ( (PHVS) ).
On January 12, 2026, Pharvaris outlined its 2026 strategic priorities centered on advancing deucrictibant through late-stage development and toward commercialization in hereditary and acquired angioedema. Following the December readout of its pivotal Phase 3 RAPIDe-3 study, which met primary and secondary endpoints for on-demand HAE treatment, the company is preparing a U.S. New Drug Application for deucrictibant in the first half of 2026, with additional marketing applications to follow, and is progressing multiple Phase 3 programs, including CHAPTER-3 for long-term HAE prophylaxis and the CREAATE trial in AAE-C1INH. Pharvaris is also extending its clinical dataset with the long-term CHAPTER-1 results, which showed sustained reductions in HAE attack rates over roughly three years, and is running the CHAPTER-4 extension to further assess long-term safety and effectiveness. Management highlighted an estimated cash runway into the first half of 2027 and recent inclusion in the Nasdaq Biotechnology Index, reinforcing the company’s financial and market positioning as it moves toward potential launch of deucrictibant and expands its visibility through upcoming investor conferences and medical congress presentations.
The most recent analyst rating on (PHVS) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
The score reflects high fundamental risk from being pre-revenue with widening losses and heavy negative free cash flow, partly offset by a low-debt balance sheet and solid equity base. Technically, price action is supportive (trading above key moving averages with neutral-to-positive momentum), while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris N.V., listed on Nasdaq, is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists, led by its candidate deucrictibant, to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company is focused on both prophylactic and on-demand treatment settings, targeting a niche but highly specialized segment of the rare disease market for angioedema therapies.
Average Trading Volume: 351,363
Technical Sentiment Signal: Buy
Current Market Cap: $1.6B
Learn more about PHVS stock on TipRanks’ Stock Analysis page.